bexarotene has been researched along with Lymphoma, T-Cell in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goerdt, S; Klemke, CD | 1 |
| Haugen, BR | 1 |
| Beyeler, M; Dummer, R | 1 |
| Crawford, G; Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC | 1 |
| Bouwhuis, SA; Davis, MD; el-Azhary, RA; Gibson, LE; Kist, JM; Knudsen, JM; McEvoy, MT; Pittelkow, MR | 1 |
| Altmeyer, P; Kreuter, A | 1 |
| Asteria, C | 1 |
| Bailly, C; Formstecher, P; Lansiaux, A | 1 |
| Bell, TJ | 1 |
| Crowley, CA; Duvic, M; Kim, Y; Martin, AG; Olsen, E; Wood, GS; Yocum, RC | 1 |
| Breneman, D; Duvic, M; Kuzel, T; Stevens, VJ; Truglia, J; Yocum, R | 1 |
| Kim, YH; Liu, HL | 1 |
4 review(s) available for bexarotene and Lymphoma, T-Cell
| Article | Year |
|---|---|
Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Cytokines; Dendritic Cells; Diphtheria Toxin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interleukin-2; Keratinocytes; Lymphoma, T-Cell; Macrophages; Mast Cells; Membrane Glycoproteins; NF-kappa B; Receptors, Chemokine; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat | 2008 |
Drugs that suppress TSH or cause central hypothyroidism.
Topics: Aged; Bexarotene; Dopamine Agonists; Glucocorticoids; Humans; Hypothyroidism; Lymphoma, T-Cell; Male; Metformin; Retinoid X Receptors; Somatostatin; Tetrahydronaphthalenes; Thyrotropin | 2009 |
[Standard and experimental therapy of cutaneous T-cell lymphoma].
Topics: Adrenal Cortex Hormones; Aminoquinolines; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell; Methotrexate; Photopheresis; Prednisone; PUVA Therapy; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, High-Energy; Recombinant Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine | 2003 |
Treatment with retinoid X receptorgamma-selective ligand (bexarotene) may cause iatrogenic central hypothyroidism.
Topics: Animals; Bexarotene; Humans; Hypothyroidism; Iatrogenic Disease; Lymphoma, T-Cell; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes | 2000 |
2 trial(s) available for bexarotene and Lymphoma, T-Cell
| Article | Year |
|---|---|
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Capsules; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Skin Neoplasms; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome | 2001 |
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Gels; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Safety; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2002 |
6 other study(ies) available for bexarotene and Lymphoma, T-Cell
| Article | Year |
|---|---|
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Drug Synergism; Drug Therapy, Combination; Humans; Interferon-alpha; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes | 2004 |
Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Topics: Adult; Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2005 |
Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome.
Topics: Aged; Bexarotene; CD8-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell; Male; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors | 2005 |
[LGD1069: an antagonist to the X retinoid receptor].
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cells, Cultured; Clinical Trials as Topic; Dimerization; Drug Eruptions; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Lymphoma, T-Cell; Mice; Rats; Receptors, Retinoic Acid; Retinoid X Receptors; Skin Neoplasms; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription Factors; Transcriptional Activation | 2000 |
T-cell lymphoma products.
Topics: Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Interleukin-2; Lymphoma, T-Cell; Proteins; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |
Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
Topics: Anticarcinogenic Agents; Bexarotene; Drug Approval; Gels; Humans; Lymphoma, T-Cell; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes | 2002 |